Using the targeting principle of neutrophil-derived CVs, we designed a multifunctional controlled-release drug delivery platform to carry nucleic-acid molecules targeting for ACMSD, which can block ACMSD expression in renal tubular epithelial cells and rescue AKI in vitro and in vivo without detection of biological toxicity. This evidence concerns the gene ACMSD and acute kidney injury.